Wilmington, United States
Ayala Pharmaceuticals is a clinical-stage oncology company that focuses on developing and commercializing small molecule therapeutics for rare cancers and aggressive tumors, as well as proprietary Lm-based antigen delivery products for more common cancers. Established in 2017 and headquartered in the United States, the company's lead candidates in development include the oral gamma secretase inhibitor AL102 for desmoid tumors, ADXS-504 for early-stage prostate cancer, and the intravenous gamma secretase inhibitor AL101 for adenoid cystic carcinoma. Notably, AL102 has received Fast Track Designation from the U.S. FDA and is currently in the Phase 3 segment of a pivotal study for patients with desmoid tumors.
The company recently secured a $25.00M Post-IPO Equity investment on 19 February 2021, with the investment coming from Redmile Group and Sio Capital. With a mission to address unmet medical needs in oncology, Ayala Pharmaceuticals is positioning itself as a promising player in the biotechnology and pharmaceutical industries.
